Expression of receptor activator of nuclear factor-κB is inversely correlated with metastatic phenotype in breast carcinoma

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 162-165

  Bhatia, Pardeep ^a   Sanders, M Melinda ^a   Hansen, Marc F ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE ATROPHY; BONE METASTASIS; BONE REMODELING; BREAST CARCINOMA; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; OSTEOBLAST; OSTEOCLAST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

BONE AND BONES; BONE REMODELING; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PHENOTYPE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS;

EID: 11344261227     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ries LAG, Eisner MP, Kosary CL, et al. editors. SEER cancer statistics review, 1975-2000. Bethesda (MD): National Cancer Institute; 2003. Available from: http://seer.cancer.gov/csr/1975_2000/.
2. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 2003;5:R136-43.
3. Kakonen SM, Mundy GR. Mechanism of osteolytic bone metastases in breast carcinoma. Cancer 2003;97:834-9.
4. Guise TA. Molecular mechanism of osteolytic bone metastases. Cancer 2000;88:2892-8.
5. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
6. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone biology. J Mol Med 2001;79:243-53.
7. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
8. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
9. Guise TA. Parathyroid hormone related protein and bone metastasis. Cancer 1997;80:1572-80.
10. Guise TA, Mundy GR. Physiological and pathological roles of parathyroid hormone-related peptide. Curr Opin Nephrol Hypertens 1996;5:307-15.
11. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinol 1999;140:4451-8.
12. Chikatsu N, Takeuchi Y, Tamura Y, et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 2000;267:632-7.
13. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001;100:18-24.
14. Heryet AR, Garter KC. Immunocytochemistry for light microscopy. In: Herrington CS, McGee JO'D, editors. Diagnostic molecular pathology. New York: IRL; 1992. p. 8-17.
15. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 2003;33:28-37.